Ascendis制药 ASND 深 沪
等待开盘 09-19 09:30:00 美东时间
199.37
-0.220
-0.11%
华盛通- 最 高200.415
- 今 开200.01
- 成交量 17.59万股
- 最 低 197.765
- 昨 收 199.59
- 总市值 120.73亿
- 52周最高 208.16
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 118.03
- 委 比 -38.75%
- 总股本 6055.44万
- 历史最高 208.16
- 量 比 0.70
- 振 幅 1.33%
- 历史最低 11.92
- 每 手 1
- 风险率 17.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多横盘迷雾下的价值火山：维昇药业-B（2561.HK）正站在价值重构临界点
在资本市场短期波动的迷雾中，真正的价值往往需要穿透股价表象才能被洞察。 自登陆港股以来，“生长发育第一股”维昇药业的股价便陷入了一场耐人寻味的横盘，既未如部分创...
09-16 10:02
PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment
BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in the Phase 3 study.
09-09 01:56
B of A Securities Maintains Buy on Ascendis Pharma, Raises Price Target to $230
B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $227 to $230.
09-02 23:41
How Do Investors Really Feel About Ascendis Pharma?
Ascendis Pharma's (NYSE:ASND) short percent of float has fallen 9.85% since its...
08-29 01:00
Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference
Ascendis Pharma announced that its executives will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, in Boston. A live webcast and replay of the presentation will be available on the company's website. Ascendis Pharma, a global biopharmaceutical company, focuses on using its TransCon technology to develop innovative therapies to address unmet medical needs. The press release also include...
08-28 20:01
JP Morgan Maintains Overweight on Ascendis Pharma, Raises Price Target to $260
JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $254 to $260.
08-19 22:17
Ascendis Pharma A/S Q2 Earnings Call Highlights Growth
Ascendis Pharma A/S (($ASND)) has held its Q2 earnings call. Read on for the ma...
08-13 10:36
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Acendis Pharma shares are trading lower following the release of its Q2 financial results.
Acendis Pharma shares are trading lower following the release of its Q2 financi...
08-08 22:27
Stifel Maintains Buy on Ascendis Pharma, Raises Price Target to $254
Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $212 to $254.
08-08 21:44
